VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation
- PMID: 29507755
- PMCID: PMC5826926
- DOI: 10.1038/s41421-018-0019-0
VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation
Abstract
N6-methyladenosine (m6A) is enriched in 3'untranslated region (3'UTR) and near stop codon of mature polyadenylated mRNAs in mammalian systems and has regulatory roles in eukaryotic mRNA transcriptome switch. Significantly, the mechanism for this modification preference remains unknown, however. Herein we report a characterization of the full m6A methyltransferase complex in HeLa cells identifying METTL3/METTL14/WTAP/VIRMA/HAKAI/ZC3H13 as the key components, and we show that VIRMA mediates preferential mRNA methylation in 3'UTR and near stop codon. Biochemical studies reveal that VIRMA recruits the catalytic core components METTL3/METTL14/WTAP to guide region-selective methylations. Around 60% of VIRMA mRNA immunoprecipitation targets manifest strong m6A enrichment in 3'UTR. Depletions of VIRMA and METTL3 induce 3'UTR lengthening of several hundred mRNAs with over 50% targets in common. VIRMA associates with polyadenylation cleavage factors CPSF5 and CPSF6 in an RNA-dependent manner. Depletion of CPSF5 leads to significant shortening of 3'UTR of over 2800 mRNAs, 84% of which are modified with m6A and have increased m6A peak density in 3'UTR and near stop codon after CPSF5 knockdown. Together, our studies provide insights into m6A deposition specificity in 3'UTR and its correlation with alternative polyadenylation.
Conflict of interest statement
C.H. is a scientific founder of the Accent Therapeutics and a member of the Scientific Advisory Committee. The remaining authors declare that they have no conflict of interest.
Figures
Similar articles
-
Structures and mechanisms of the RNA m 6A writer.Acta Biochim Biophys Sin (Shanghai). 2024 Sep 6. doi: 10.3724/abbs.2024152. Online ahead of print. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 39238441
-
Wilms' tumor 1-associating protein complex regulates alternative splicing and polyadenylation at potential G-quadruplex-forming splice site sequences.J Biol Chem. 2021 Nov;297(5):101248. doi: 10.1016/j.jbc.2021.101248. Epub 2021 Sep 25. J Biol Chem. 2021. PMID: 34582888 Free PMC article.
-
The drive to generate multiple forms of oncogenic cyclin D1 transcripts in mantle cell lymphoma.Biomark Res. 2017 May 8;5:16. doi: 10.1186/s40364-017-0094-7. eCollection 2017. Biomark Res. 2017. PMID: 28503306 Free PMC article.
-
A birds'-eye view of the activity and specificity of the mRNA m6 A methyltransferase complex.Wiley Interdiscip Rev RNA. 2021 Jan;12(1):e1618. doi: 10.1002/wrna.1618. Epub 2020 Jul 19. Wiley Interdiscip Rev RNA. 2021. PMID: 32686365 Review.
-
Dynamic Variations of 3'UTR Length Reprogram the mRNA Regulatory Landscape.Biomedicines. 2021 Oct 28;9(11):1560. doi: 10.3390/biomedicines9111560. Biomedicines. 2021. PMID: 34829789 Free PMC article. Review.
Cited by
-
mRNA modifications in cardiovascular biology and disease: with a focus on m6A modification.Cardiovasc Res. 2022 Jun 22;118(7):1680-1692. doi: 10.1093/cvr/cvab160. Cardiovasc Res. 2022. PMID: 33956076 Free PMC article. Review.
-
Novel Roles of RNA m6A Methylation Regulators in the Occurrence of Alzheimer's Disease and the Subtype Classification.Int J Mol Sci. 2022 Sep 15;23(18):10766. doi: 10.3390/ijms231810766. Int J Mol Sci. 2022. PMID: 36142676 Free PMC article.
-
No significant change of N6 -methyladenosine modification landscape in mouse brain after morphine exposure.Brain Behav. 2024 Jan;14(1):e3350. doi: 10.1002/brb3.3350. Brain Behav. 2024. PMID: 38376052 Free PMC article.
-
Nuclear m6 A reader YTHDC1 suppresses proximal alternative polyadenylation sites by interfering with the 3' processing machinery.EMBO Rep. 2022 Nov 7;23(11):e54686. doi: 10.15252/embr.202254686. Epub 2022 Sep 12. EMBO Rep. 2022. PMID: 36094741 Free PMC article.
-
A methylation-related signature for predicting prognosis and sensitivity to first-line therapies in gastric cancer.J Gastrointest Oncol. 2023 Dec 31;14(6):2354-2372. doi: 10.21037/jgo-23-770. Epub 2023 Dec 27. J Gastrointest Oncol. 2023. PMID: 38196539 Free PMC article.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
